170504 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
#2ANTIBODY BINDING TO C-MET AND USE THEREOF
#3COMBINATION DRUG
#4EVOLUTION OF FLUOROGENIC SENSORS
#5Methods for Evaluating Angiogenesis
#6Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
#7COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#8IN VITRO CELL-BASED POTENCY ASSAY
#9USE OF EXTRACELLULAR VESICLES AND MICRONUCLEI OF CIRCULATING STROMAL CELLS AS PAN-CANCER BIOMARKERS FOR PREDICTING CLINICAL OUTCOMES
#10ANTI-AXL ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF AND METHODS FOR MAKING AND USING THE SAME
#11METHODS AND SYSTEMS FOR CHARACTERIZING PROTEOFORMS OF SIGNIFICANT PROTEINS OF INTEREST
#12MMP-14 OR TIMP POTENCY ASSAY FOR MESENCHYMAL STEM CELLS
#13BIOMARKERS
#14APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS
#15COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES
#16CYCLIC PEPTIDES FOR TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND MUTATIONS THEREOF FOR DRUG DELIVERY
#17COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES
#18Methods and Compositions for Oral Cancer Risk
#19ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#20MODULAR BIOSENSOR FOR RECEPTOR TYROSINE KINASE ACTIVITY
#21METHOD FOR PREDICTING PROGNOSIS OF BREAST CANCER PATIENT USING CTC EXPRESSING C-MET
#22BLOOD BIOMARKERS IN LONG-COVID-19
#23TREATMENT OF SOLID TUMORS
#24TRUNCATED DOMAIN IV EGFR AND USES THEREOF
#25FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#26MONOCLONAL ANTIBODIES AND BISPECIFIC ANTIBODY AGAINST C-MET
#27METHOD OF USING AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATABLE ANTIBODY TO DETECT THE PRESENCE OR ABSENCE OF A CLEAVING AGENT AND EGFR
#28METHOD OF ISOLATING AND ANALYZING CIRCULATING TUMOR CELLS
#29COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
#30NUCLEIC ACID LINKED IMMUNE-SANDWICH ASSAY (NULISA)
#31METHODS AND DEVICES FOR DETECTION OF ORTHOGONAL CLASSES OF DISEASE BIOMARKERS
#32MEANS AND METHODS APPLYING sFlt-1/PIGF OR ENDOGLIN/PIGF RATIO TO RULE OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
#33IMMUNOFLUORESCENCE AND FLUORESCENT-BASED NUCLEIC ACID ANALYSIS ON A SINGLE SAMPLE
#34Aptamer-Based Fluorescence Polarization Detection Method for Extracellular Vesicles and Its Application
#35BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE
#36SYSTEMS AND METHODS FOR THE ANALYSIS OF BIOLOGICAL SAMPLES
#37SMO HUMAN ANTIBODY
#38TRUNCATED DOMAIN IV EGFR AND USES THEREOF
#39USE OF TCTP AS BIOMARKER FOR PREDICTING EFFICACY, PROGNOSIS OF IMMUNOTHERAPY OR RESISTANCE THERETO, AND TARGET OF IMMUNOTHERAPY FOR ENHANCING EFFICACY
#40EXTRACELLULAR VESICLE DRUG ANALYSIS FOR REAL-TIME MONITORING OF TARGETED THERAPY
#41HUMANIZED ANTI-EGFR VIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
#42ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF
#43COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#44DIAGNOSIS AND TREATMENT OF ECTOPIC ENDOMETRIOSIS
#45TGF- B receptor II isoform, fusion peptide, methods of treatment and methods in vitro
#464H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
#47NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#48CELLS EXPRESSING HER3 ANTIGEN-BINDING MOLECULES
#49SFLT1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS
#50LATERAL FLOW ANALYSIS AND BREAST CANCER
#51LIQUID BIOPSY YIELD ENHANCEMENT
#52TARGET ANALYTE DETECTION METHOD BASED ON PROXIMITY PROTEOLYSIS REACTION
#53DETECTION OF BIOMARKERS
#54Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof
#55METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS
#56N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
#57A RATIO BETWEEN PLGF AND SFLT1 IS PREDICTIVE FOR NEURAL INVASION IN PATIENTS SUFFERING FROM PANCREATIC CANCER
#58METHODS AND COMPOSITIONS FOR TREATING CANCER
#59ASSAYS FOR FIXED DOSE COMBINATIONS
#60Human otic progenitor identification and isolation
#61FUSION PROTEINS AND METHODS THEREOF
#62PREDICTION OF RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPIES USING EPIREGULIN AND AMPHIREGULIN
#63METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS
#64THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER
#65HISTOCHEMICAL SYSTEMS AND METHODS FOR EVALUATING EGFR AND EGFR LIGAND EXPRESSION IN TUMOR SAMPLES
#66ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#67DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA
#68Methods of measuring signaling pathway activity for selection of therapeutic agents
#69Biomarker for Predicting Prognosis of Radiotherapy for Lung Cancer
#70AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3)
#71Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
#72NOVEL ANTI-FGFR2B ANTIBODIES
#73NOVEL ANTI-FGFR2B ANTIBODIES
#74Composition for treating or diagnosing osteoarthritis targeting ACVR2B
#75Methods for Identifying Cancer Patients for Combination Treatment
#76Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
#77Modular point-of-care devices, systems, and uses thereof
#78THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER
#79Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#80ANTI-C-MET AGONIST ANTIBODY AND USE THEREOF
#81NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#82METHOD FOR ENHANCING TUMOR GROWTH
#83ANTI-AXL ANTIBODIES
#84Method for treating cancer based on expression levels of translationally controlled tumor protein (TCTP)
#85Anti-IGFBP-3R antibodies and methods of treating an IGFBP-3R expressing cancer
#86Full length kinase activity-conformation reporter
#87Circulating tumor markers for meningiomas
#88KLOTHO BETA
#89ANTIBODY QUANTIFICATION IN BIOLOGICAL SAMPLES
#90NOVEL C-MET AND TMX2 ANTIBODIES
#91TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD
#92Antigen-binding constructs targeting HER2
#93Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#94METHODS FOR CAPTURING, ISOLATION, AND TARGETING OF CIRCULATING TUMOR CELLS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF
#95EGFR blocking agents for the therapeutic treatment of myopia
#96BI-SPECIFIC BINDING MOLECULES
#97Nucleic acid linked immune-sandwich assay (NULISA)
#98KLOTHO BETA
#99Compositions and methods for growth factor modulation
#100Nucleic acid linked immune-sandwich assay (NULISA)
#101Liquid biopsy yield enhancement
#102METHODS OF TREATING CANCER BASED ON IDENTIFYING MUTATIONS IN THE EXTRACELLULAR DOMAIN III OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE
#103METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES
#104ANTIBODY FOR HER2 CONCOMITANT DIAGNOSIS IMMUNOHISTOCHEMICAL DETECTION AND APPLICATION THEREOF
#105IL13Rα2 binding agents and use thereof
#106Methods for Evaluating Angiogenesis
#107Biomarkers for assessing breast cancer
#108METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#109ASSESSMENT OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED OF HAVING AN INFECTION, HAVING A SOFA SCORE LOWER THAN TWO
#110IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNE-BASED THERAPY
#111Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#112Anti-EGFR antibody polypeptide
#113T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR
#114Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#115Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
#116EGFRVIII ANTIBODY AND CONJUGATE, AND PREPARATION METHOD AND USE THEREOF
#117Activatable antibodies that bind epidermal growth factor receptor and methods thereof
#118WBP2 AS A CO-PROGNOSTIC FACTOR WITH HER2 FOR STRATIFICATION OF PATIENTS FOR TREATMENT
#119TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD
#120Reagents and Methods for Breast Cancer Detection
#121Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
#122Method and apparatus for analysis of protein-protein interaction
#123Capture and release of particles from liquid samples
#124METHOD FOR ESTIMATING THERAPEUTIC EFFICACY
#125METHODS OF PRODUCING CIRCULATING ANALYTE PROFILES AND DEVICES FOR PRACTICING SAME
#126HLA G-MODIFIED CELLS AND METHODS
#127Methods of assessing cellular breast samples and compositions for use in practicing the same
#128Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies
#129Anti-c-Met antibody and use thereof
#130Anti-epidermal growth factor receptor (EGFR) antibodies
#131ANTI-VEGF ANTIBODY
#132DILUENT FOR FLUORESCENT NANO PARTICLES, KIT FOR IMMUNOFLUORESCENT STAINING WHICH UTILIZES SAME, SOLUTION FOR IMMUNOFLUORESCENT STAINING, IMMUNOFLUORESCENT STAINING METHOD, AND GENE STAINING METHOD
#133Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#134COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#135METHODS OF CLASSIFYING DIFFUSE LARGE B-CELL LYMPHOMA
#136Compositions and methods for programmable sensing and control through combinatorial molecular interactions
#137Predicting Cancer Treatment Outcome With T-DM1
#138EGFR-binding agents and uses thereof
#139HLA G-modified cells and methods
#140Full length kinase activity-conformation reporter
#141Biomarker Panel For Diagnosing Cancer
#142Methods for discovering protein-protein interactions
#143PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY
#144METHODS AND COMPOSITIONS FOR PROVIDING PREECLAMPSIA ASSESSMENT
#145Peptoid compound, and derivative, salt, preparation method and use thereof
#146In vitro method for identifying a pregnancy related disease
#147Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
#148Method of Identifying Transmembrane Protein-interacting Compounds
#149Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas
#150Conjugates of IL13Rα2 binding agents and use thereof in cancer treatment
#151Disruption of EGFR-SAR1 interaction for cancer treatment
#152Methods of treating an IGFBP-3R expressing cancer using anti-IGFBP-3R antibodies
#153METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#154METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
#155NOVEL EGFR VARIANT
#156Fusion proteins and methods thereof
#157Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof
#158Human otic progenitor identification and isolation
#159Anti-Axl antagonistic antibodies
#160Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2
#161EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF
#162Monoclonal antibodies to fibroblast growth factor receptor 2
#163Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
#164Methods involving Menain screening for inhibitors of cancer invasion and metastasis
#165Methods of detecting tumor cells
#166ARRAY-BASED PEPTIDE LIBRARIES FOR THERAPEUTIC ANTIBODY CHARACTERIZATION
#167TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
#168METHODS OF DIAGNOSING, CLASSIFYING AND TREATING ENDOMETRIAL CANCER AND PRECANCER
#169Compositions and methods for growth factor modulation
#170Agents for use in the therapeutic treatment of hyperopia
#171PROGNOSIS OF SEROUS OVARIAN CANCER USING BIOMARKERS
#172Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
#173Antibody against EGFRvIII and use thereof
#174Methods of measuring signaling pathway activity for selection of therapeutic agents
#175Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway
#176Anti-Axl antibodies
#177Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#178ERBB4 activator screening assay
#179Prognostic method and kits useful in said method
#180ENRICHMENT AND IDENTIFICATION OF FETAL MATERIAL
#181ANTI-ErbB2 ANTIBODIES
#182Reagents and Methods for Breast Cancer Detection
#183Antigen-binding constructs targeting HER2
#184Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant III
#185Method of Identifying Transmembrane Protein-interacting Compounds
#186In vitro method for identifying a pregnancy related disease
#187Modular point-of-care devices, systems, and uses thereof
#188EGFR MUTATIONS
#189Modular point-of-care devices, systems, and uses thereof
#190Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#191SYNTHETIC ANTIBODY MIMIC PEPTIDES
#192Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#193WBP2 AS A CO-PROGNOSTIC FACTOR WITH HER2 FOR STRATIFICATION OF PATIENTS FOR TREATMENT
#194Methods for determining prognosis of colorectal cancer
#195Endoglin Antibodies
#196METHODS OF TREATING FGFR3 RELATED CONDITIONS
#197Binding proteins based on di-ubiquitin muteins and methods for generation
#198Truncated Her2 SRM/MRM assay
#199Anti-VEGFR antibody and uses thereof
#200METHOD FOR IMPROVED HEPATOCELLULAR CANCER DIAGNOSIS
#201Biomarkers Related to Treatment of Cancer with HER3 and EGFR Inhibitors
#202Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein
#203Methods of determining patient response by measurement of HER-3
#204Methods for treatment of metastatic thyroid cancer using a PDGFR-α inhibitor
#205Methods and systems for screening using microcapillary arrays
#206Peptidomimetics for imaging the ghrelin receptor
#207Compositions and methods for diagnosing breast cancer
#208Test support method for supporting prediction of pathological complete response (pCR) using fluorescent nanoparticles
#209IL13Rα2 binding agents and use thereof in cancer treatment
#210Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity
#211Conjugated porphyrin carbon quantum dots for targeted photodynamic therapy
#212Detection of ovarian cancer using antibody arrays
#213The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
#214Identification of immunogenic MHC class II peptides for immune-based therapy
#215REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER
#216Monoclonal antibodies to fibroblast growth factor receptor 2
#217IGF-1R antibody and its use for the diagnosis of cancer
#218Micro-array devices for capturing cells in blood and methods of their use
#219Anti-ANG2 antibody
#220Biomarker panel for diagnosing cancer
#221Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
#222Nucleic acid aptamers binding to vascular endothelial growth factor receptors
#223Compositions and Methods for the Diagnosis and Treatment of Lupus Nephritis
#224COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS
#225COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF
#226Mutant smoothened and methods of using the same
#227Synergistic cancer treatment
#228METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
#229COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#230COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
#231CIRCULATING TUMOR CELL ASSAY
#232Sialylated fetuin-A as a marker of immunotherapy efficacy
#233Anti-Axl antagonistic antibodies
#234WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#235Fibroblast growth factor receptors as diagnostic markers of acquired sensory neuronopathies
#236METHODS OF MEASURING ERBB SIGNALING PATHWAY ACTIVITY TO DIAGNOSE AND TREAT CANCER PATIENTS
#237DILUENT FOR FLUORESCENT NANO PARTICLES, KIT FOR IMMUNOFLUORESCENT STAINING WHICH UTILIZES SAME, SOLUTION FOR IMMUNOFLUORESCENT STAINING, IMMUNOFLUORESCENT STAINING METHOD, AND GENE STAINING METHOD
#238Method of Identifying Transmembrane Protein-interacting Compounds
#239Aptamers and diagnostic methods for detecting the EGF receptor
#240Biomarkers to identify patients that will respond to treatment and treating such patients
#241Auto-active and intracellular mutant of MET
#242Predicting genetically stable recombinant protein production in early cell line development
#243THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER
#244PREDICTING TUMOR RESPONSES TO ANTIBODIES AGAINST HEPATOCYTE GROWTH FACTOR (HGF) AND/OR ITS COGNATE RECEPTOR, C-MET
#245Biomarkers for assessing breast cancer
#246HLA G-modified cells and methods
#247Cancer cell growth inhibitor, anticancer agent, and method for screening same, as well as novel compound
#248METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS
#249Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
#250ALK AND ROS KINASE IN CANCER
#251Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
#252NT-pro ANP and SFlt-1 For The Differentiation Between Circulatory And Ischemic Events
#253Method of treating cancer based on identifying mutations in the extracellular domain III of epidermal growth factor receptor gene
#254Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#255METHODS FOR IDENTIFYING COMPOUNDS THAT ALTER THE ACTIVITY OF IRHOM POLYPEPTIDES AND USE THEREOF
#256PDGFR RNA aptamers
#257ANTI-VEGFR ANTIBODY AND USES THEREOF
#258Methods for predicting response of triple-negative breast cancer to therapy
#259PREDICTING RESPONSE TO A VEGF ANTAGONIST
#260HEPATOCELLULAR CARCINOMA MARKER
#261Anti-epidermal growth factor receptor (EGFR) antibodies
#262Compositions and methods for regulating glucose metabolism
#263Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#264Anti-EGFR conformational single domain antibodies and uses thereof
#265Compositions and methods for growth factor modulation
#266Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
#267Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#268METHODS OF TREATING MELANOMA
#269Soluble AXL receptor tyrosine kinase in the diagnosis of cancer
#270FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
#271Anti-Axl antibodies
#272Molecular analysis of tumor samples
#273Small molecule detection and localization method based on MALDI imaging mass spectrometry
#274Reduction of TGFβ signaling in myeloid cells in the treatment of cancer
#275Modulation of growth hormone receptor expression and insulin-like growth factor expression
#276Anti-Axl antibodies
#277Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
#278Synthetic antibody mimic peptides
#279Quantifying met protein for cancer treatment
#280Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor
#281Antibodies specifically binding to HER3
#282METHODS OF ISOLATING DISTINCT PANCREATIC CELL TYPES
#283MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
#284Methods of Determining Patient Response by Measurement of HER-2 Expression
#285Methods of diagnosing and treating complications of pregnancy
#286INDOLE-LIKE TRK RECEPTOR ANTAGONISTS
#287Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
#288Endoglin antibodies
#289Targeted therapy to restore radioactive iodine transport in thyroid cancer
#290Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
#291Modular point-of-care devices, systems, and uses thereof
#292Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
#293Modular point-of-care devices, systems, and uses thereof
#294Method for detecting an FGFR3/TACC3 fusion protein, or encoding gene thereof
#295Diagnosis of cancer by detecting auto-antibodies against EGF-receptor
#296Pyrimidine FGFR4 inhibitors
#297DETECTING PODOCYTE INJURY IN DIABETIC NEPHROPATHY AND GLOMERULONEPHRITIS
#298Methods of detecting a tumor expressing fibroblast growth factor receptor 2
#299SIGNALING PATHWAYS IN TISSUES FROM INFLAMMATORY BOWEL DISEASE PATIENTS
#300Quantifying Her2 protein for optimal cancer therapy